IL282251A - Compositions and methods for treatment of liver disease - Google Patents
Compositions and methods for treatment of liver diseaseInfo
- Publication number
- IL282251A IL282251A IL282251A IL28225121A IL282251A IL 282251 A IL282251 A IL 282251A IL 282251 A IL282251 A IL 282251A IL 28225121 A IL28225121 A IL 28225121A IL 282251 A IL282251 A IL 282251A
- Authority
- IL
- Israel
- Prior art keywords
- preparations
- methods
- liver diseases
- treating liver
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747903P | 2018-10-19 | 2018-10-19 | |
| PCT/US2019/056910 WO2020081920A1 (en) | 2018-10-19 | 2019-10-18 | Compositions and methods for treatment of liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL282251A true IL282251A (en) | 2021-05-31 |
Family
ID=70284106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282251A IL282251A (en) | 2018-10-19 | 2021-04-12 | Compositions and methods for treatment of liver disease |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210388073A1 (https=) |
| EP (1) | EP3866852A4 (https=) |
| JP (2) | JP2022512735A (https=) |
| KR (1) | KR20210081366A (https=) |
| CN (2) | CN120305401A (https=) |
| AU (1) | AU2019361120A1 (https=) |
| CA (1) | CA3117098A1 (https=) |
| IL (1) | IL282251A (https=) |
| WO (1) | WO2020081920A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154648A1 (en) | 2019-09-16 | 2021-03-25 | Opsidio, LLC | Anti-stem cell factor antibodies and methods of use thereof |
| US20220378843A1 (en) * | 2019-11-01 | 2022-12-01 | Figene, Llc | Fibroblast-based therapy for treatment of sclerosing cholangitis |
| CN117487010B (zh) * | 2022-08-02 | 2025-02-14 | 东莞市朋志生物科技有限公司 | 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒 |
| AU2024232439A1 (en) * | 2023-03-03 | 2025-08-28 | Karydo Therapeutix, Inc. | Antibody or antigen-binding fragment of same |
| CN117045680B (zh) * | 2023-10-12 | 2023-12-08 | 北京国卫生物科技有限公司 | 促进肝脏再生的干细胞制剂及其制备方法 |
| WO2025179048A2 (en) * | 2024-02-20 | 2025-08-28 | Ecogenome Llc | Antibodies that bind dach1 and methods of use |
| CN119331100B (zh) * | 2024-10-16 | 2025-07-25 | 天津大学 | 特异性结合25-羟基维生素d的单克隆抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014770A3 (en) * | 1997-10-29 | 2009-02-18 | Genentech, Inc. | WNT-1 Iinduced secreted polypeptide WISP-2 |
| EP1177796B1 (en) * | 1999-04-27 | 2011-04-27 | Mitsubishi Tanabe Pharma Corporation | Medicament for prevention or therapeutic treatment of liver disease |
| JPWO2003014345A1 (ja) * | 2001-08-08 | 2004-11-25 | 味の素株式会社 | 肝星細胞活性化に関与する遺伝子パネル |
| CA2801066C (en) * | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| KR20160138580A (ko) * | 2014-04-15 | 2016-12-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Wisp1에 결합하는 항원 결합 단백질 |
| AU2015360502A1 (en) * | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US11015196B2 (en) * | 2016-05-20 | 2021-05-25 | The General Hospital Corporation | Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases |
-
2019
- 2019-10-18 CN CN202411435476.8A patent/CN120305401A/zh active Pending
- 2019-10-18 EP EP19873989.8A patent/EP3866852A4/en active Pending
- 2019-10-18 WO PCT/US2019/056910 patent/WO2020081920A1/en not_active Ceased
- 2019-10-18 CN CN201980083971.8A patent/CN113271971A/zh active Pending
- 2019-10-18 CA CA3117098A patent/CA3117098A1/en active Pending
- 2019-10-18 AU AU2019361120A patent/AU2019361120A1/en active Pending
- 2019-10-18 US US17/286,011 patent/US20210388073A1/en not_active Abandoned
- 2019-10-18 JP JP2021521144A patent/JP2022512735A/ja not_active Withdrawn
- 2019-10-18 KR KR1020217014607A patent/KR20210081366A/ko active Pending
-
2021
- 2021-04-12 IL IL282251A patent/IL282251A/en unknown
-
2024
- 2024-09-04 US US18/824,691 patent/US20250223344A1/en active Pending
- 2024-09-20 JP JP2024163238A patent/JP2025011102A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025011102A (ja) | 2025-01-23 |
| US20210388073A1 (en) | 2021-12-16 |
| WO2020081920A1 (en) | 2020-04-23 |
| AU2019361120A1 (en) | 2021-05-13 |
| CN120305401A (zh) | 2025-07-15 |
| JP2022512735A (ja) | 2022-02-07 |
| EP3866852A4 (en) | 2022-07-06 |
| EP3866852A1 (en) | 2021-08-25 |
| KR20210081366A (ko) | 2021-07-01 |
| US20250223344A1 (en) | 2025-07-10 |
| CA3117098A1 (en) | 2020-04-23 |
| CN113271971A (zh) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281109A (en) | Compositions and methods for enhancing triplex and nuclease-based gene editing | |
| IL282225A (en) | Compositions and methods for immunotherapy | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| IL282251A (en) | Compositions and methods for treatment of liver disease | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL272514A (en) | Compositions and methods for modifying genomes | |
| IL268684A (en) | Compositions and methods for immunooncology | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL268788A (en) | Compositions and methods for enhanced gene expression | |
| IL282372A (en) | Haploid induction compositions and methods for use therefor | |
| IL261082A (en) | Compositions and methods for modifying genomes | |
| IL290792A (en) | Compositions and methods for the treatment of viral infections | |
| IL281015A (en) | Methods and compositions for the modification of plants | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| IL269490B (en) | Surface treatment methods and compositions therefor | |
| IL268872A (en) | Methods and compositions for treating cancers using antisense | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL283644A (en) | Compositions and methods for immunotherapy | |
| IL273705B (en) | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | |
| IL280145A (en) | Methods and compositions using recombinant dendritic cells for cancer therapy | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| IL264070A (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| IL261740A (en) | Compositions and methods for treatment of type vii collagen deficiencies |